EV/EBITDA Multiple: Quince Therapeutics Inc (QNCX)

Corporate company logo of quincetx.com (QNCX)

Quince Therapeutics (QNCX) develops innovative therapies for orphan diseases. As a valuation tool, the EV/EBITDA chart demonstrates a figure of 0.00, which is critical given the fierce competition with industry behemoths. The business relies on a method of encapsulating enzymes into the patient's erythrocytes to reduce the immune response. However, the lack of revenue and dependence on FDA approval create significant financial risks.

QNCX (Quince Therapeutics, Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 10/12/2026

Quince Therapeutics Inc (QNCX) - metric breakdowns and financial figures

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Initial company analysis:QNCX (quincetx.com)
Product sample of Quince Therapeutics, Inc.

To assess long-term risks, the investor analyzes the EV/EBITDA ratio of Quince Therapeutics (QNCX), which relates the total enterprise value to its operating profit before interest and taxes. This chart reflects the balance between market expectations and the actual efficiency of Quince Therapeutics, where valuation stability depends directly on the monetization potential of its unique erythrocyte-based drug delivery platform.

Who Quince Therapeutics competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ascendispharma.com ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics Corp - EV/EBITDA Multiple|Company Value to EBITDA Rhythm Pharmaceuticals Inc|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Pharmaceuticals|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (Soleno Therapeutics Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization amicusrx.com FOLD|89bio Pharma (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Corp|Enterprise Value to EBITDA Ratio MBX Corp (MBX)|EV/EBITDA Multiple ALT|Enterprise Value to EBITDA Ratio Aardvark Therapeutics Inc AARD|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sagimet Biosciences, Inc. SGMT|BioAge - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Biomea Fusion Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation GUTS (Fractyl)|VTVT (vTv Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|Agape ATP Corp. (ATPC) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pluri-biotech.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SYBX|EV/EBITDA Multiple LPCN|Matinas BioPharma Holdings - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SPRB (sprucebiosciences.com)|Enterprise Value to Operating Income Before Depreciation Ratio GLTO (galecto.com)|CTCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LUMO|organovo.com (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Radius Health - Business Value to Operating Income Before Depreciation